Categories: News

Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024

SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the first quarter 2024 before market open on Tuesday, April 30, 2024.

The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio.

About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.

Media Contact
press@nautilus.bio

Investor Contact
investorrelations@nautilus.bio

Staff

Recent Posts

Adia Labs Launches Turnkey Clinic Model for Chiropractic Practices with BoldMD

Winter Park, Florida--(Newsfile Corp. - December 17, 2025) - Adia Labs, a division of Adia…

2 hours ago

Population Health Partners and dacadoo Announce Strategic Partnership to Advance Digital Health Engagement and Outcome-Based Healthcare

New York and Zurich, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Population Health Partners, L.P., a…

2 hours ago

Population Health Partners and dacadoo Announce Strategic Partnership to Advance Digital Health Engagement and Outcome-Based Healthcare

New York and Zurich, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Population Health Partners, L.P., a…

2 hours ago

Incyclix Bio Expands Board of Directors with Appointment of Dr. Kimberly Blackwell

RESEARCH TRIANGLE PARK, N.C., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation…

2 hours ago

Incyclix Bio Expands Board of Directors with Appointment of Dr. Kimberly Blackwell

RESEARCH TRIANGLE PARK, N.C., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation…

2 hours ago

Vaso Corporation Announces Fifth Extension of Sales Representation Agreement with GE HealthCare

Vaso Corporation137 Commercial StreetPlainview, New York 11803Tel: (516) 997-4600 Fax: (516) 997-2299 Investor Contact:Jonathan NewtonInvestor…

2 hours ago